Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Australia shares close over 2% lower as coronavirus cases surge in hotspot

share with twitter share with LinkedIn share with facebook
09/09/2020 | 02:51am EDT

* Tech stocks end at near 4-week low

* Victoria reports biggest daily rise in three days

* Weak oil futures pull energy stocks to over 4-month low

Sept 9 (Reuters) - Australian shares finished at their lowest in over two months on Wednesday, following a tech-led rout on Wall Street, as a spike in infections in the country's coronavirus hot spot Victoria weighed on sentiment.

Victoria on Wednesday reported its biggest rise in daily cases in three days as the state boosted its contact tracing programme to ease the spread of the virus.

The S&P/ASX 200 index fell 2.2% to 5,878.6 at the close of trade, its lowest since June 30.

That follows Wall Street's overnight losses as heavy-weight technology companies tumbled for a third straight session and sent the Nasdaq into correction territory.

"I'm more and more certain that we have seen the peak particularly in U.S. tech stocks, and they were the only things holding up the broader market," said Brad Smoling, managing director at Smoling Stockbroking.

"And naturally Australia is going to sell-off in sympathy with that."

Local tech stocks fell 2.4%, with Afterpay giving up 1.3% and accounting software firm Xero shedding 2.1%.

Also hurting sentiment was news that AstraZeneca, a front runner in the global COVID-19 vaccine race, said it had paused a late-stage trial of its vaccine candidate following an unexplained illness in a study participant.

However, the Australian deputy chief medical officer Nick Coatsworth said the country was not worried about the pause in the trials.

Energy stocks, down 4.7%, led declines as oil prices extended their steep losses into Wednesday.

Woodside Petroleum tumbled 4.4%, while Santos fell 5.4% and were the biggest drags on the sub-index.

Top lenders Commonwealth Bank of Australia and Westpac Banking Corp were the biggest percentage losers among financials, down 2.5% and 3.3%, respectively.

New Zealand's benchmark S&P/NZX 50 index lost 1.3% to finish the session at 11,739.11, with financials and utilities tumbling the most.

(Reporting by Arpit Nayak in Bengaluru; Editing by Amy Caren Daniel)

Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -1.31% 8109 Delayed Quote.8.02%
COMMONWEALTH BANK OF AUSTRALIA 1.11% 70.01 End-of-day quote.-12.38%
S&P/ASX 200 0.85% 6229.4 Real-time Quote.-7.59%
SANTOS LIMITED 0.58% 5.16 End-of-day quote.-36.92%
WESTPAC BANKING CORPORATION 0.64% 18.78 End-of-day quote.-22.49%
WOODSIDE PETROLEUM LTD 0.71% 18.55 End-of-day quote.-46.04%
XERO LIMITED 1.66% 116.45 End-of-day quote.45.56%
share with twitter share with LinkedIn share with facebook
All news about ASTRAZENECA PLC
12:50pFrance's Ose to enrol up to 400 for 'T-cell' coronavirus vaccine trials
12:50pFrance's Ose to enroll up to 400 for 'T-cell' coronavirus vaccine trials
12:40pChina's Sinovac vaccine is safe, Brazil institute says
12:06pBrazil's Butantan says tests show vaccine by China's Sinovac is safe
10:31aASTRAZENECA : Receives a Sell rating from Goldman Sachs
04:08aASTRAZENECA : Trixeo Aerosphere recommended for approval in the EU by CHMP for t..
04:08aASTRAZENECA : Forxiga recommended for approval in the EU by CHMP for heart failu..
02:38aASTRAZENECA : wins two approval recommendations from EU agency
10/16Pfizer says earliest U.S. filing for COVID-19 vaccine would be late November
10/16EXPLAINER : When will COVID-19 vaccines be generally available in the United Sta..
More news
Financials (USD)
Sales 2020 26 714 M - -
Net income 2020 3 076 M - -
Net Debt 2020 13 172 M - -
P/E ratio 2020 37,1x
Yield 2020 3,48%
Capitalization 106 B 138 B -
EV / Sales 2020 4,48x
EV / Sales 2021 3,90x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 118,12 $
Last Close Price 81,09 $
Spread / Highest target 91,7%
Spread / Average Target 45,7%
Spread / Lowest Target -18,6%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON1.53%389 921
ROCHE HOLDING AG-0.56%291 357
PFIZER INC.-3.14%210 884
MERCK & CO., INC.-12.23%201 909
NOVARTIS AG-14.09%190 074